FIELD: medicine; therapy; endocrinology.
SUBSTANCE: present group of inventions and concerns treating a condition associated with hyperinsulinemia. That is ensured by administering BET bromodonite inhibitor compounds.
EFFECT: it provides effective treatment of hyperinsulinemia, particularly related to insulinoma, by reducing expression of genes required for beta-cell functioning.
22 cl, 9 ex, 16 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| BI- AND POLYCYCLIC SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES, USEFUL AS RHO-KINASE INHIBITORS | 2009 |
|
RU2532481C2 |
| DEUTERATED BENZYL BENZENE DERIVATES AND METHODS FOR USE | 2009 |
|
RU2509773C2 |
| NEUROACTIVE COMPOUNDS AND THEIR APPLICATION METHODS | 2015 |
|
RU2764702C2 |
| 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES EFFECTIVE AS Rho-KINASE INHIBITORS | 2009 |
|
RU2528229C2 |
| PYRAZOLPYRIMIDINE COMPOUNDS JAK INHIBITORS AND METHODS | 2009 |
|
RU2539568C2 |
| USING MAGNESIUM STEARATE IN DRY INHALATION POWDER FORMULATIONS | 2011 |
|
RU2580890C2 |
| NEW BICYCLIC PYRAZOLE DERIVATIVES | 2018 |
|
RU2781426C2 |
| SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES AS Rho-KINASE INHIBITORS | 2007 |
|
RU2455302C2 |
| PIPERADINYL-SUBSTITUTED ISOQUINOLONE DERIVATIVES AS Rho-KINASE INHIBITORS | 2006 |
|
RU2414467C2 |
| NEW FIVE-MEMBER HETEROCYCLES, THEIR PREPARING, THEIR APPLYING AND PHARMACEUTICAL PREPARATIONS COMPRISING THEREOF | 1998 |
|
RU2240326C2 |
